BeOne Medicines

BeOne Medicines BeOne Medicines is a global oncology company that is discovering and developing innovative treatments that are more accessible to cancer patients worldwide.

BeOne Medicines is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. With a growing global team of nearly 12,000 colleagues spanning six continents, the Company is committed to radically improving access to medicines for far more patients who need them. To learn more about BeOne, please visit www.beonemedicines.com and follow us on LinkedIn, X, Facebook and Instagram. We all share the responsibility to report adverse events observed with our products so that they may be investigated, actioned, and communicated accordingly. To report an adverse event or side effect, please talk to your healthcare provider and contact us here: https://beonemedicines.com/contact-us/report-adverse-events/

As more patients turn to AI for answers, it’s critical that these tools support, not replace, conversations with clinici...
01/28/2026

As more patients turn to AI for answers, it’s critical that these tools support, not replace, conversations with clinicians and advocates. We’re proud to partner with Katie Couric to help patients responsibly harness AI tools, so they can navigate cancer care with clarity and confidence.

A practical guide to using AI tools without falling into misinformation or anxiety spirals.

01/27/2026

At BeOne, we know cancer is too complex to solve alone and we’re stronger together.

To kick off season two of the Cancer Has No Borders podcast, our SVP and Chief Medical Officer, Solid Tumors, Mark Lanasa, joins to talk about the value of partnerships with patients to better understand the cancer journey, and close gaps in education, diagnosis, and access.

Watch the full episode here: https://youtu.be/xq8Q2VdzUG8?si=GmGAuRntuTAejPrt

Or listen on your favorite platform:
Apple: https://podcasts.apple.com/us/podcast/episode-13-inside-beones-global-oncology-pipeline-with/id1784166790?i=1000746869490
Spotify: https://open.spotify.com/episode/4YVTCmlJ7d4eHwsfc5oIX7?si=p09tNhCNRbWvaSx8soJKnQ
Amazon: https://www.amazon.com/Cancer-Has-No-Borders/dp/B0DPW4WSN3

01/26/2026
BeOne is proud to support today’s Cancer Support Community South Bay   roundtable - bringing patients, caregivers, and p...
01/23/2026

BeOne is proud to support today’s Cancer Support Community South Bay roundtable - bringing patients, caregivers, and providers together to raise awareness of insurance access barriers and keep cancer treatment decisions where they belong: between patients and their doctors.

The hidden burdens of cancer go beyond treatment.

Insurance delays and denials can stand between patients and the care they need.

Join us for a FREE panel discussion + community roundtable focused on putting patients over paperwork and protecting access to prescribed care.

🗓 Friday, January 23, 2026
📍 FREE IN-PERSON & ONLINE
🍽️ Lunch 12:30–1pm
🕐 Panel 1–2pm PST
📌 CSC South Bay + Zoom

Hear from patients, caregivers, and providers.
Share your story. Ask questions. Be part of the conversation.

✨ Lunch, raffle, and a small gift for in-person attendees
👉 Register at www.CSCSouthBay.org

01/22/2026

As part of our commitment to improving access to cancer care around the world, we’re pleased to announce that the BeOne Care Foundation has shared a grant with Federatia Asociatiilor Bolnavilor de Cancer din Romania.

This funding will provide free oncological testing in rural areas of Romania, delivering medical consultations and blood tests to people facing barriers to accessing care.

It’s one example of how we continually support partner organizations and make a real difference to patient communities across the globe. By working together, we can create meaningful change so that access to cancer care is not defined by geography.

01/16/2026

As we look ahead to 2026, our commitment remains unwavering – standing up for patients, everywhere.

From day one, we’ve set out to defy the status quo, reimagining how life-changing cancer therapies are discovered, developed, and delivered to those who need them most.

For us, access isn’t an aspiration – it’s an imperative. With ~2 million patients worldwide already treated with our medicines, we know this is just the beginning.

As ASCO   comes to a close, we’re reflecting on an inspiring few days of collaboration and forward momentum in GI oncolo...
01/10/2026

As ASCO comes to a close, we’re reflecting on an inspiring few days of collaboration and forward momentum in GI oncology.

One of the clear highlights of the meeting was the presentation of positive Phase 3 results in patients with HER2+ GEA. The strong interest and discussion around these data underscore the potential impact in upper .

A huge thank you to the researchers, clinicians, partners, and advocates who contributed to the valuable dialogue throughout the Symposium.

We’re looking forward to what comes next!

01/09/2026

Gastroesophageal adenocarcinoma, or GEA, is a type of cancer that includes cancers of the stomach, gastroesophageal junction, and esophagus.

At this year’s ASCO Symposium, is highlighting important Phase 3 data in GEA.

Our Head of Global Medical Affairs for Solid Tumors, Nadeem Ghali, shares his take on this data from the congress floor.

12/24/2025

From all of us at , we wish you a joyful, peaceful holiday season!

Enjoy a restful break with your loved ones, and we’ll see you in 2026!

12/22/2025

As 2025 comes to a close, we’re taking a moment to look back and celebrate the progress we’ve made in the last 12 months.

It’s been an amazing year of insights, breakthroughs, and innovations. Thank you to everyone who has been part of the journey of our shared mission! Bring on 2026!

Patients with cancer are increasingly becoming the CEOs of their own health, turning to AI to interpret symptoms, unders...
12/19/2025

Patients with cancer are increasingly becoming the CEOs of their own health, turning to AI to interpret symptoms, understand scans, and prepare for clinical conversations. It's a powerful shift that's redefining the patient-clinician relationship and creating new possibilities for how blood cancer care is delivered.

The question isn't whether AI will play a role in cancer care. It's how we ensure these tools are accurate, trustworthy, and designed to serve patients and caregivers at their most vulnerable moments.

In STAT, BeOne explores five ways AI is transforming the patient blood cancer journey, and the collaborative work needed across the patient advocacy and broader cancer community to unlock its full potential.

Read the full article here:

Artificial intelligence (AI) is rapidly changing how people seek health information, interpret health data, and participate in decisions about their

Ready to unwrap the year?Swipe to dive into BeOne 2025 – the highlights, surprises and all the moments that made us say ...
12/17/2025

Ready to unwrap the year?

Swipe to dive into BeOne 2025 – the highlights, surprises and all the moments that made us say ‘wow’!

Behind every statistic are the people who made it possible – our incredible team and the patients who guide our work.

To everyone who contributed to our initiatives in 2025 – thank you! We couldn’t do this without you.

Address

55 Cambridge Parkway, Suite 700W
Cambridge, MA
02142

Telephone

+18778285568

Website

https://www.linkedin.com/company/beonemedicines

Alerts

Be the first to know and let us send you an email when BeOne Medicines posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram